A better understanding of the hepatic metabolic pathways affected by fulminant hepatic failure (FHF) would help develop nutritional support and other nonsurgical medical therapies for FHF. We used an isolated perfused liver system in combination with a mass-balance model of hepatic intermediary metabolism to generate a comprehensive map of metabolic alterations in the liver in FHF. To induce FHF, rats were fasted for 36 hours, during which they received 2 D-galactosamine injections. The livers were then perfused for 60 minutes via the portal vein with amino acid-supplemented Eagle minimal essential medium containing 3% wt/ vol bovine serum albumin and oxygenated with 95% O 2 /5% CO 2 . Control rats were fasted for 36 hours with no other treatment before perfusion. FHF rat livers exhibited reduced amino acid uptake, a switch from gluconeogenesis to glycolysis, and a decrease in urea synthesis, but no change in ammonia consumption compared with normal fasted rat livers. Mass-balance analysis showed that hepatic glucose synthesis was inhibited as a result of a reduction in amino acid entry into the tricarboxylic acid cycle by anaplerosis. Furthermore, FHF inhibited intrahepatic aspartate synthesis, which resulted in a 50% reduction in urea cycle flux. Urea synthesis by conversion of exogenous arginine to ornithine was unchanged. Ammonia removal was quantitatively maintained by glutamine synthesis from glutamate and a decrease in the conversion of glutamate to ␣-ketoglutarate. Mass-balance analysis of hepatic metabolism will be useful in characterizing changes during FHF, and in elucidating the effects of nutritional supplements and other treatments on hepatic function. (HEPATOLOGY 2001;34:360-371.)
Since the late 1980s, orthotopic liver transplantation has become the only widely accepted treatment for fulminant hepatic failure (FHF). [1] [2] [3] [4] Because of the severe shortage in donor organs, various alternatives aimed at providing a "substitute" liver, such as xenogeneic whole liver perfusion 5 and extracorporeal bioartificial liver devices, 6, 7 are being developed. Such systems, which can be used as a bridge to transplantation or provide temporary relief during the most acute phase of hepatic failure, are promising, although technically complex and expensive. It has been hypothesized that hepatic encephalopathy may result from the elevation of circulating levels of putative toxins such as ammonia, mercaptans, short-chain fatty acids, [8] [9] [10] and an abnormal amino acid profile. [11] [12] [13] In FHF patients, alterations in amino acid concentrations in systemic plasma have been characterized by several investigators, 14, 15 which led to the use of solutions rich in branchedchain amino acids (BCAA) for the treatment of hepatic encephalopathy. 16, 17 These approaches, which were largely unsuccessful, aimed at counteracting the observed shifts in metabolite levels in the systemic circulation; however, systemic changes in metabolite levels do not solely reflect alterations in liver function, but also changes in whole-body metabolism. Therefore, a better understanding of which pathways are directly affected in the liver during hepatic failure may provide a rational basis for developing a nutritional support or other nonsurgical, conventional medical therapy.
To characterize the metabolic state of the liver in the absence of systemic effects, previous investigators have used isolated perfused liver systems to study amino acid metabolism in cirrhotic rats [18] [19] [20] [21] and gluconeogenesis in the D-galactosamine-treated FHF rat model. 22 These studies were limited by the small number of parameters measured, which prevented a more global and comprehensive analysis of the metabolic changes induced by FHF in the liver. Using a large number of metabolite measurements is helpful in drawing a comprehensive map of the metabolic state of the organ; however, because of the complexity and large number of interrelationships between metabolites, mathematical models are necessary to analyze the data. A popular modeling approach used in biotechnological applications is based on the assumption that the observed rates of consumption or production of extracellular metabolites are coupled via the intracellular metabolic network of enzymes. Because this network is well known, one can apply the basic principle of mass conservation to each intracellular metabolite. Under steady-state conditions, strictly intracellular metabolites remain at constant levels, and intracellular rates of reactions through major pathways are linearly related to the measured rates of change of extracellular metabolites by the known stoichiometry of the metabolic network. 23, 24 We recently developed a mass-balance model to characterize changes in liver metabolism during the hypermetabolic response to injury. 25 Liver injury induced by D-galactosamine is morphologically similar to acute viral 26, 27 or drug-induced 28 hepatitis in hu-mans, and it can produce hepatic encephalopathy or brain edema in animal models. [29] [30] [31] In a previous study, we characterized the survival and blood chemistry in D-galactosamineinduced hepatic failure in rats. 32 In this study, we investigated the metabolic changes induced by D-galactosamine treatment in rat livers. We measured a wide range of parameters pertinent to amino acid and glucose metabolism, and estimated intrahepatic metabolic fluxes using a mass-balance model. We found that D-galactosamine treatment significantly decreases hepatic gluconeogenesis, which correlated with a reduction in amino acid entry into various points of the tricarboxylic acid (TCA) cycle. Furthermore, FHF inhibited intrahepatic aspartate synthesis, which resulted in a 50% reduction in urea cycle flux. Urea synthesis by conversion of exogenous arginine to ornithine was unchanged. Ammonia removal was quantitatively maintained by glutamine synthesis from glutamate and a decrease in the conversion of glutamate to ␣-ketoglutarate.
utes during the 60-minute perfusion period and stored at Ϫ80°C for later analysis. After 10 and 50 minutes of recirculating perfusion, inflow and outflow perfusate samples were taken for the measurement of oxygen partial pressure and analyzed immediately with an automatic blood gas analyzer (238 Blood Gas Analyzer; Chiron Diagnostics Co., Pittsburgh, PA). At the end of the 60-minute recirculating perfusion, the whole liver was removed, weighed, and immediately frozen in liquid nitrogen. Frozen liver tissues were weighed again after freeze-drying for 48 hours to determine the dry/wet weight ratio.
Assessment of Liver Injury. Heparinized blood samples were centrifuged to obtain plasma. Aspartate transaminase (AST) and alanine transaminase (ALT) activities in the plasma were determined using commercially available kits (Sigma Chemical Co.; kits nos. 58 and 59) as parameters of liver injury.
Metabolite Assays. Glucose, lactate, and ammonia concentrations in the perfusate or plasma samples were determined using enzymatic and colorimetric methods with commercially available assay kits (Sigma Chemical Co.; kit nos. 315, 735, and 171, respectively). Urea content in the perfusate was measured based on its specific reaction with diacetyl monoxime using a commercial assay kit (Sigma Chemical Co.; kit no. 535-A). The concentrations of acetoacetate and ␤-hy- droxybutyrate were assayed enzymatically by monitoring the production or consumption of reduced nicotinamide adenine dinucleotide (NADH) via the reaction catalyzed by ␤-hydroxybutyrate dehydrogenase as described elsewhere. 37 Amino Acid Analysis. Individual amino acid concentrations in the perfusate and plasma samples were quantified by an automated highperformance liquid chromatography system that consisted of a Waters 2690 Separations Module (Waters Co., Milford, MA) and Waters 474 Scanning Fluorescence Detector (Waters Co.) set at an excitation of 250 nm and an emission of 395 nm, both controlled by a Millennium 32 software system (Waters Co.). The samples were deproteinated by mixing with an equal volume of acetonitrile and derivatized with the Waters AccQ-Fluor Reagent Kit (Waters Co.). Separation was performed using a modification of Cohen's procedures 38 provided by Waters Co., which was adapted for a 4-eluent system of buffers. Eluents A and B were prepared by dissolving 14.8 g of sodium acetate trihydrate, 607 mg of triethylamine, and 0.5 g of sodium azide in 1 L water; the pH was adjusted to 5.70 (eluent A) or 6.80 (eluent B) with 50% phosphoric acid. Eluent C was 100% acetonitrile, and eluent D was 10% vol/vol methanol in water. Separations were performed on a AccQ Tag Amino Acid Analysis Column (Waters Co.) at 39°C using the following linear gradient profile: 0% to 5% eluent C with B level at 5% and D level at 0% over 17.5 minutes; 5% to 87.5% eluent B with C level at 12.5% and D level at 0% over 1 minute; 12.5% to 15% eluent C with A level at 22% and D level at 0% over 7.5 minutes (total time ϭ 26 minutes). The column was then washed with 60% eluent C ϩ 40% eluent D for 1.5 minutes, followed by 95% eluent A ϩ 5% eluent B for 13 minutes, and re-equilibrated with 60% eluent C ϩ 40% eluent D for 19 minutes before the next injection. Data from samples were compared with an amino acid standard mixture consisting of Amino Acid Standard H (Pierce, Rockford, IL), to which asparagine, glutamine, and ornithine were added.
Calculation of Rates of Consumption or Production of Metabolites and
Statistical Analysis. The rate of consumption or release of each extracellular metabolite by the liver during perfusion was determined by taking the slope of a line fitting concentration versus time data, with appropriate corrections to account for changes in perfusate volume resulting from repeated sampling. The best-fit line was calculated by regression analysis. Data are expressed as mean Ϯ SEM. Comparisons were made using the Student t test, and P Ͻ .05 was considered significant.
Metabolic Flux Determination by Mass-Balance Analysis. The network models of liver metabolism were constructed based on known stoichiometric relationships between the reactions of intermediary metabolism. Two models were formulated, one corresponding to a gluconeogenic state (I) and the other to a glycolytic state (II). The pathways included in both models are: 1) TCA cycle, 2) urea cycle, 3) ␤-oxidation, 4) amino acid oxidation, and 5) ketone body synthesis. In addition, the reactions of gluconegenesis were added to model I, whereas glycolysis reactions were included in model II. The following pathways are assumed to be inhibited by fasting and therefore were not included in either model: 1) glycogen synthesis, 2) fatty acid synthesis, and 3) irreversible, energy-requiring steps for de novo amino acid biosynthesis. Table 2 lists the stoichiometry and the relevant enzymes of all the reactions included in both models. In model I, which is tailored to a gluconeogenic liver, fluxes through pyruvate kinase (flux no. 8) and pyruvate dehydrogenase (flux no. 10) were set to 0. In model II, which is tailored to a glycolytic liver, the flux through pyruvate carboxylase (flux no. 9) was set to 0. It is not possible to have these 3 enzymes active simultaneously, because it would create a futile cycle and lead to a mathematical singularity in the network. The calculation of intrahepatic fluxes follows a procedure described previously, 25 which is summarized in the Appendix at the end of this article. Fluxes were calculated for each perfused liver and then averaged in each group (FHF and control).
RESULTS

Gross Liver
Damage by D-Galactosamine. Ten rats were given D-galactosamine following the protocol described in Materials and Methods. Because 2 of 10 (20%) animals had died before liver perfusion, the remaining 8 rats were used as the FHF group. AST, ALT, glucose, and ammonia levels in peripheral plasma of control and FHF rats are shown in Table 3 . Plasma AST and ALT were elevated over 100-fold in the FHF group compared with the control group (P Ͻ .01 for AST, P Ͻ .001 for ALT). Ammonia also increased significantly in the FHF group compared with the control group (P Ͻ .05), but there was no significant difference in plasma glucose levels. D-Galactosamine treatment did not induce hepatic edema, because the dry/wet weight ratio of liver tissue was similar in both FHF rats and control rats.
Amino Acid Profiles in Arterial Plasma. On the whole, amino acid concentrations were elevated in the FHF group, with significant differences in the levels of aspartate, asparagine, glutamine, proline, methionine, phenylalanine, arginine, ornithine, valine, and leucine ( Table 3 ). Concentrations of total amino acids and gluconeogenic amino acids were also increased. The molar ratio of BCAA to aromatic amino acids (valine ϩ leucine ϩ isoleucine)/(tyrosine ϩ phenylalanine) was significantly reduced in the FHF group (P Ͻ .05).
Changes in Metabolites During Liver Perfusion. Figure 1 shows the net changes in glucose, lactate, urea, ammonia, and ketone bodies in the perfusate and the partial oxygen pressure levels during liver perfusions. The calculated production rates of individual metabolites are shown in Table 4 . Perfused livers from control rats released glucose, which likely represents gluconeogenesis in these fasted rats. In contrast, FHF rat livers took up glucose, which is indicative of glycolysis. The difference in the glucose production rate was statistically significant by the unpaired t test (P Ͻ .001). Lactate was released from livers in both groups during the 60-minute perfusion period; FHF rat livers produced significantly more than those from control rats (P Ͻ .001). Urea production from FHF rat livers was significantly inhibited compared with controls (P Ͻ .01). Although no ammonia was added to the perfusate, it did contain an initial amount of ammonia (192 Ϯ 42 mol/L in the control group and 254 Ϯ 30 mol/L in the FHF group; not statistically different), which is likely the result of a partial degradation of glutamine in the perfusate. Ammonia was taken up by control and FHF livers at similar rates. Ketone bodies (the sum of acetoacetate and ␤-hydroxybutyrate) accumulated in the perfusate at a lower rate with FHF rat livers than controls (P Ͻ .001). The oxygen-consumption rates, which were determined based on the difference in the oxygen levels in the inlet and the outlet of liver after 10 and 50 minutes of recirculating perfusion, did not significantly vary over this period. The average oxygen-consumption rates are reported in Table 4 . The average oxygen consumption of the livers in the FHF group was less than two thirds that of livers in the control group (P Ͻ .01). The molar ratio of acetoacetate to ␤-hydroxybutyrate (ketone body ratio) at each time point was not significantly different between the 2 groups (Fig. 2) .
Amino Acid Metabolism in Perfused Livers. Table 4 shows the uptake rates of individual amino acids by the perfused livers. In the FHF group, most of the major gluconeogenic amino acids were taken up at lower rates than in the control group, or even switched to a net release, with statistical differences for asparagine, serine, glycine, glutamate, glutamine, histidine, 
Oxaloacetate ϩ acetyl-CoA 3 citrate citrate synthase Ϫ0.52 Ϯ 3.4 11.9 Ϯ 4.6 § 13
Citrate Cysteine uptake
2 glycine ϩ NAD ϩ 3 serine ϩ NADH ϩ CO2 ϩ NH4 ϩ glycine synthase 11.9 Ϯ 1.8 3.9 Ϯ 1.9 § 32 Glycine uptake
Phenylalanine ϩ H4biopterin ϩ O2 3 H2biopterin ϩ tyrosine phenylalanine hydroxylase 5.5 Ϯ 0. Tyrosine uptake threonine, alanine, proline, methionine, tyrosine, valine, leucine, and isoleucine. The uptake rate of the sum of all gluconeogenic amino acids was significantly lower in the FHF group. The uptake of BCAA was also significantly affected. As for aromatic amino acids (AAA), a significant difference was seen with the uptake rate of tyrosine, but not phenylalanine. The uptake of arginine and ornithine, which are intermediates of the urea cycle, were not influenced by D-galactosamine treatment. Considering all amino acids together shows a net release in the FHF group, whereas there was a net uptake in the control group. Intrahepatic Fluxes by Mass-Balance Analysis. From the rates of change of extrahepatic metabolites measured during the perfusions (shown in Table 4 ), intrahepatic fluxes were calculated by the mass-balance method described in Materials and Methods and the Appendix. Two different models, one reflecting a gluconeogenic and the other a glycolytic state, were used for the mass-balance calculations. In the gluconeogenic model, because rats were fasted for a long time (36 hours), the pyruvate kinase flux (flux no. 8) and the pyruvate dehydrogenase flux (flux no. 10) were assumed to be negligible. In the glycolytic model, the pyruvate carboxylase flux (flux no. 9) was assumed to be 0. Calculations for control rats and FHF rats were performed using both models. Analysis of the consistency index revealed that control data were much better fitted by the gluconeogenic model, whereas the FHF data fitted the glycolytic model best. Intrahepatic fluxes were calculated accordingly and are shown in the last 2 columns of Table 2 . Statistically significant differences were found for gluconeogenesis/glycolysis (flux nos. 1-7, 9, 11), TCA cycle (nos. 12, 13-17), urea cycle (nos. [18] [19] [20] , gluconeogenic amino acid oxidation pathways (nos. 25-27, 30-32, 34, 35, 40-48, 50) , ␤-oxidation (no. 51), ketogenesis (nos. 52-55), and mitochondrial electron transport (nos. [56] [57] [58] . These and other key fluxes are summarized in Fig. 2 , in which amino acid pathways are grouped according to their points of entry into the metabolic network. TCA cycle fluxes were not significantly inhibited in FHF rats except for the fluxes from ␣-ketoglutarate to oxaloacetate. Amino acid entries into the TCA cycle, gluconeogenesis, and ketogenesis pathways were broadly inhibited in the FHF group.
DISCUSSION
Using an isolated perfused liver system, we were able to characterize the metabolic changes specific to the liver following D-galactosamine treatment in rats, and thus delineate the impact of liver versus peripheral tissues on the changes in metabolite levels observed in the circulation of FHF rats. Livers switched from a net uptake of amino acids in the normal fasted group to a net release of amino acids in the FHF group, including the BCAA. Furthermore, the net uptake of AAA was significantly reduced by D-galactosamine treatment. D-Galactosamine treatment also inhibited the hepatic production of glucose and ketone bodies, while favoring the release of lactate, suggesting a switch from mitochondrial oxidation to glycolysis for intrahepatic energy production. Despite these changes, plasma glucose levels did not change appreciably, which may be a result of compensatory gluconeogenesis in the kidney 39, 40 and/or inhibition of uptake by peripheral organs. We also developed a metabolite mass-balance model that enabled us to elucidate alterations in intrahepatic metabolic fluxes that account for the observed changes in hepatic consumption and secretion of metabolites. The model shows that D-galactosamine inhibited intrahepatic aspartate and arginine synthesis about 2-fold. As a result, ammonia detoxification by the urea cycle was reduced proportionally, and about one third to one half of the urea synthesized in the FHF rat liver was derived from the degradation of exogenous arginine by arginase. In addition, D-galactosamine caused a reduction in TCA cycle flux between ␣-ketoglutarate and oxaloacetate, which is the likely cause of the inhibition of the flux from oxaloacetate to phosphoenolpyruvate (PEP) in the gluconeogenic pathway. Interestingly, oxaloacetate was not derived from pyruvate via the pyruvate carboxylase reaction, but rather came from anaplerotic reactions that involve the deamination and entry of amino acids into various branch points of the TCA cycle. Thus, the inhibition of gluconeogenesis in the FHF rat livers can be directly related to the overall inhibition of gluconeogenic amino acid uptake.
Patients with acute liver failure typically exhibit elevated plasma levels of AAA and methionine, normal or slightly increased BCAA levels, and a broad increase in other amino acid concentrations. 12, 14, 15 Furthermore, an important clinical parameter in FHF is the BCAA/AAA or Fisher's ratio, which decreases with increasing severity of hepatic dysfunction. 41 Plasma amino acid levels in D-galactosamine-treated rats fol- ‡Gluconeogenic amino acids include aspartate, asparagine, serine, glycine, glutamate, glutamine, histidine, threonine, alanine, proline, methionine, lysine, cysteine, tyrosine, phenylalanine, arginine, valine, and isoleucine. lowed similar changes. On the other hand, induction of hepatic failure in the rat required a 36-hour fast, which induced ketogenesis. This situation may be different in the human. Clearly, our liver failure model can only approximate the clinically encountered disease, and studies using various animal models will be necessary to determine which features are common to FHF in general, and which ones are specific to the insult (D-galactosamine, carbon tetrachloride, acetaminophen, etc.). Phenylalanine metabolism in perfused livers was not significantly affected by D-galactosamine treatment while phenylalanine levels were elevated in FHF rats, suggesting that there are significant nonhepatic contributions to the increased phenylalanine circulating pool in FHF rats. One possibility is muscle catabolism-dependent release of AAA in FHF. 42 Tyrosine uptake was inhibited, leading to a net release in perfused livers of FHF rats; however, tyrosine levels in the circulation of FHF rats were extremely variable, which precludes any conclusion as to the origin of plasma tyrosine in our animal model. Methionine uptake in perfused livers from FHF rats was inhibited, which correlates well with the observed increase in plasma levels.
D-Galactosamine treatment increased the plasma levels of most other amino acids, which correlated with the switch from measured amino acid uptake to release or decrease in uptake by perfused livers, although alterations in amino acid uptake were generally much more dramatic than the changes in systemic levels. For example, the plasma levels of gluconeogenic amino acids increased less than 2-fold, whereas the corresponding hepatic uptake decreased about 5-fold. The inhibition of amino acid uptake, which is largely mediated by energy-dependent amino acid transporter systems, may result from the decrease in hepatic adenosine triphosphate (ATP) levels in D-galactosamine-treated rats. 22, 43 This would be consistent with the observed improvement in hepatic functions and energetic state by treatments that increase plasma amino acid levels many fold, [43] [44] [45] thus abolishing the steep concentration gradient normally existing between the intracellular and extracellular compartments. Conversely, processes that cause the entry of extracellular ions into cells exacerbate the effect of D-galactosamine, presumably because of the inability to restore normal ionic balance via ATPases. 46 Our data show a decrease in oxygen uptake rate by perfused livers from FHF rats compared with the controls. This response differs from a recent clinical study showing elevated hepatic oxygen uptake in liver failure patients. 47 In addition, Makin et al. 48 previously found in rats given a single dose of D-galactosamine (1.1 g/kg) a transient increase in oxygen uptake rate, as well as hepatic blood flow peaking at 48 hours and FIG. 1. Glucose (A), lactate (B), urea (C), ammonia (D), and ketone body (E) released into the perfusate and oxygen consumption (F) during liver perfusions. The livers from normal control rats (E, n ϭ 6) and rats with FHF induced by D-galactosamine (•, n ϭ 6) were perfused in situ with a recirculating system for 60 minutes with the perfusate containing physiologic concentrations of glucose, amino acids, and albumin. Data are represented as mean Ϯ SE. In (A) to (E), a decreasing concentration of the metabolites indicates uptake into the liver from the perfusate, and significant differences from the control group at each time point are indicated by *(P Ͻ .05) and **(P Ͻ .01). (F) shows the oxygen uptake rate measured after 10 minutes and 50 minutes of perfusion.
returning to control levels at the 72-hour time point. The reduced oxygen uptake in our study, which we measured in ex vivo preparations at the 72-hour time point, may reflect more severe hepatic damage as a result of the method of FHF induction using 2 injections of D-galactosamine (1.4 g/kg each), which causes 83% mortality at 7 days. Further studies at other points will be required to assess whether a transient hypermetabolic phase occurs in our model as well.
Ozawa et al. previously correlated a decrease in arterial ketone body ratio with the accumulation of several amino acids, including alanine, proline, tyrosine, and phenylalanine, in the plasma of postoperative patients with liver failure. 49 The decreased ketone body ratio presumably reflects a decrease in mitochondrial redox potential, or intramitochondrial NAD ϩ /NADH, 50 which would inhibit reactions requiring NAD ϩ as a cofactor, such as those catalyzed by citrate synthase and ␣-ketoglutarate dehydrogenase, and result in a decreased turnover rate of the TCA cycle and entry of amino acid carbon backbones into the TCA cycle. Contrary to this hypothesis, the ketone body ratio in the perfusate was not different with normal fasted and FHF rat livers.
The drop in ammonia consumption by the urea cycle, about 55 mol/g dry liver/h, was largely compensated by an increase of about 65 mol/g dry liver/h in ammonia consumption associated with the reduction in conversion of glutamate to ␣-ketoglutarate (flux no. 41, 44 mol/g dry liver/h) and the reversal of the glutamine to glutamate reaction (flux no. 43, 21 mol/g dry liver/h), which probably explains why no significant change in the release of free ammonia from perfused livers was recorded in response to D-galactosamine treatment. Thus, different results may be obtained if other hepatotoxins that target pericentral hepatocytes are used. Furthermore, this finding is consistent with the notion that FHF-induced hyperammonemia is caused by the metabolism of glutamine to ammonia and alanine in the gut. 51 Another possible contributor is the inhibition of ammonia uptake by skeletal muscle, the latter of which metabolizes over 50% of the ammonia under normal physiologic conditions. 52 Recent studies suggest that improving ammonia removal by skeletal muscle may be an effective means of reducing systemic ammonia levels in FHF. 44, 51 It is noteworthy that D-galactosamine does not show a preferential target zone of damage along the hepatic acinus. 53 Because urea synthesis and glutamine synthesis are expressed in different regions of the hepatic acinus, 54 different results may be obtained when using hepatotoxins that exhibit regio-selectivity, such as acetaminophen. 55 Metabolic flux analysis, which balances the major input and output metabolites according to well-known stoichiometric constraints, was able to systematically identify pathway fluxes that were altered by D-galactosamine treatment. Because of the complexity and large number of reactions present in the liver, only the major pathways were included in the stoichiometric model. Most of the pathways that were ignored contribute relatively little to the overall carbon and nitrogen balances. De novo protein synthesis was neglected because of the difficulty in measuring this parameter in a quantitative fashion in perfused livers. We previously evaluated the impact of this assumption in fasted livers, 25 and found that about 30% of the total nitrogen uptake is not accounted for. The impact on intermediary metabolism was nevertheless small, because it only altered TCA cycle fluxes by 10% to 15%. It is expected that the impact would be even smaller in the FHF group, because protein synthesis is inhibited during FHF. We also did not include the pentose phosphate pathway and DNA synthesis. The pentose phosphate pathway plays an important role in de novo nucleotide synthesis; in addition, a previous report indicated a D-galactosamine stress-induced increase in glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of the pentose phosphate pathway. 56 The effect of this pathway would most likely be to draw glucose-6-phosphate away from the glycolytic pathway, which would have little impact on the TCA cycle, because there was no flux through pyruvate dehydrogenase.
It is a well-established limitation of metabolite balancing that when the number of branching points in the metabolic network becomes large, as is the case in our model, additional constraints are needed to prevent the occurrence of singularities. For example, in fasted livers, we assumed that fluxes through pyruvate kinase and pyruvate dehydrogenase were *P Ͻ .01 compared with control. †P Ͻ .05 compared with control. ‡Gluconeogenic amino acids include aspartate, asparagine, serine, glycine, glutamate, glutamine, histidine, threonine, alanine, proline, methionine, lysine, cysteine, tyrosine, phenylalanine, arginine, valine, and isoleucine. negligible, whereas in FHF livers, we assumed that pyruvate carboxylase was completely inhibited to avoid futile cycling between pyruvate, oxaloacetate, and phosphoenolpyruvate. The assumptions used for fasted livers are based on common knowledge. The assumptions used in the other case correspond to glycolysis, a state that was experimentally observed in FHF livers. We also attempted to fit both models to each one of the conditions studied, and found good consistency between model and experimental data when the "gluconeogenic" model was fitted to fasted liver data and the "glycolytic" model to FHF liver data.
Based on the model flux calculations, the reduction of flux through the anaplerotic reaction that converts glutamate to ␣-ketoglutarate and reversal of glutamine to glutamate conversion correlated with the inhibition of hepatic aspartate synthesis in FHF rats, which is consistent with the widely accepted notion that the aspartate used by the urea cycle is almost entirely generated by transamination of oxaloacetate by glutamate. The inhibition of aspartate synthesis provides a plausible explanation for the 50% reduction of citrulline to arginine conversion in FHF rat livers. The latter reaction is metabolically coupled to citrulline formation from ornithine in the urea cycle, which was also inhibited. Previous studies in laboratory animals and isolated hepatocytes treated with D-galactosamine showed that pharmacologic inhibition of ornithine carbamoyltransferase and elevation of free ammonium levels both can increase the availability of mitochondrial carbamoyl phosphate to the cytosolic compartment for synthesis of orotic acid, the precursor of pyrimidine synthesis. [57] [58] [59] Because D-galactosamine depletes uridine pools in liver, 60 Table 2 are shown on this simplified network. Arrows indicate the direction of reaction assumed in the model. Values shown are for control/FHF livers in mol/g dry liver/h, and a statistically significant difference is indicated by *(P Ͻ .05). A negative value indicates that flux is in the opposite direction of the arrow. G-6-P, glucose 6-phosphate; F-6-P, fructose 6-phosphate; G-3-P, glyceraldehyde 3-phosphate; PEP, phosphoenolpyruvate; TG, triacylglycerol; ␣-KGA, ␣-ketoglutarate; ACAC, acetoacetate; KB, ketone bodies (acetoacetate ϩ ␤-hydroxybutyrate). Amino acids are abbreviated using the standard 3-letter convention. Extrahepatic metabolites that are transported across the cell membrane and that feed into branch points of the network are denoted by the subscript ex. to distinguish between intrahepatic and extrahepatic pools. Amino acid degradation pathways are grouped according to the points of entry into the TCA cycle, gluconeogenesis, and ketogenesis pathways.
represent an endogenous mechanism that stimulates hepatic pyrimidine synthesis in D-galactosamine-treated rats.
Ornithine given exogenously in the form of L-ornithine-L-aspartate has been shown to lower ammonia levels in the circulation, via a mechanism that likely involves glutamine synthesis from ornithine in skeletal muscle. 44 In this study, we found that maintenance of the uptake and conversion of exogenous arginine to urea in FHF resulted in an unchanged rate of ornithine export from the liver. Thus, by maintaining ornithine output, the liver may help sustain this process at the whole-body level. Furthermore, the availability of ornithine may be important for the synthesis of polyamines via ornithine decarboxylase, which has stimulatory effects on hepatic DNA synthesis. 61, 62 It is noteworthy that the aspartate moiety of L-ornithine-L-aspartate could also contribute to ammonia removal by supplying aspartate to the urea cycle. Increased urea synthesis has been documented in cirrhotic rats and patients treated with L-ornithine-L-aspartate. 63, 64 Whether the availability of intracellular aspartate is rate-limiting for urea synthesis in acute hepatic failure remains to be determined, because the capacity for urea synthesis is reportedly reduced in this condition. 65 Another important finding of the metabolic flux analysis model is that D-galactosamine causes the activation of pyruvate kinase and the glycolysis pathway. The switch from gluconeogenesis to glycolysis may be due to the depletion of ATP and probable accumulation of adenosine monophosphate in liver tissue as a result of FHF. 43 Adenosine monophosphate is an important allosteric inhibitor of fructose 1,6-bisphosphatase and stimulator of 6-phospho-1-fructokinase. Furthermore, decreased activity of gluconeogenic enzymes 22, 66 and increased pyruvate kinase activity 56 have been reported in response to D-galactosamine treatment in rats. With the induction of glycolysis in FHF rat livers, there was no concomitant activation of pyruvate dehydrogenase to convert pyruvate to acetyl-CoA, which led to a significant increase in lactate release. The primary source of acetyl-CoA was triglycerides via ␤-oxidation of fatty acids in both normal and FHF rat livers, the majority of which were used for ketone body production, with little consumption of acetyl-CoA in the TCA cycle.
We conclude that in a largely lethal D-galactosamineinduced liver failure model, hepatic glucose production is completely arrested and the liver switches to a glycolytic mode even in a fasted animal. Alterations in the periphery appear to effectively compensate to maintain blood glucose levels. D-Galactosamine also inhibits intrahepatic aspartate synthesis, which results in an inhibition of ammonia detoxification by the urea cycle. A significant fraction of urea synthesis in FHF livers is a result of the conversion of exogenous arginine to ornithine. Hepatic ammonia detoxification appears to be maintained chiefly by reduced deamination of glutamate and a switch from glutamine degradation to glutamine synthesis, whereas an increased release of ammonia from peripheral tissues is likely the cause of hyperammonemia. Further studies using metabolic flux analysis of failing livers will be useful in characterizing changes in the liver metabolic state during the course of the disease, as well as in elucidating the effects of nutritional supplements such as L-ornithine-L-aspartate and other treatments on hepatic function during FHF.
APPENDIX
Calculation of Intrahepatic Fluxes by Mass-Balance Analysis. To estimate the effect of FHF on intracellular fluxes, a network model of metabolism was constructed based on accepted stoichiometric relationships 67 between the major metabolites involved in liver intermediary metabolism. The observation that the FHF livers took up glucose and released lactate led to the formulation of 2 model states, in which one corresponded to a gluconeogenic state (I), and the other to a glycolytic state (II). The pathways included in both states are: 1) TCA cycle, 2) urea cycle, 3) ␤-oxidation, 4) amino acid oxidation, and 5) ketone body synthesis. In addition, state I included gluconeogenesis, and state II included glycolysis. The following pathways were assumed to be inhibited by fasting, and therefore were not included in either model states: glycogen synthesis, fatty acid synthesis, and irreversible, energy-requiring steps in de novo amino acid biosynthesis. Table 2 lists the stoichiometry and the relevant enzymes of the reactions included in both model states. In model state I, which is tailored to the gluconeogenic liver, fluxes through pyruvate kinase (flux no. 8) and pyruvate dehydrogenase (flux no. 10) were set to 0. In model state II, which is tailored to a glycolytic liver, the flux through pyruvate carboxylase (flux no. 9) was set to 0. While all 3 enzymes are putative housekeeping enzymes and therefore likely to be expressed to some degree at all times, these assumptions were necessary to avoid including futile cycles in the models, which would have rendered the problems mathematically unsolvable. When performing net flux calculations, pathway fluxes through metabolic cycles become unobservable unless the reactions of the cycle include cofactors (e.g., ATP, NADH, or NADPH) around which additional balances can be drawn. Conversely, a cyclic pathway can be considered detached from the rest of the metabolic network if the reactions of the cycle do not contribute to additional constraints such as cofactor balances. Therefore, neither the presence nor absence of the futile cycle around pyruvate, oxaloacetate, or phosphoenolpyruvate should impact the flux distribution in the remainder of the metabolic network.
The stoichiometric coefficients of the reactions in Table 2 were collected into a matrix S, where each element s ij was the coefficient of metabolite i in reaction j. It follows that S has dimension M ϫ N, where M is the number of metabolites and N is the number of reactions. Using S, a system of linear equations representing material balance equations around each metabolite in the network was succinctly written in matrix form:
where each element x i of x is the intracellular concentration of metabolite i, and element v j of v is the net rate of conversion in reaction j. Assuming the liver is in a metabolic steady state during the perfusion, the intracellular levels of metabolites are constant, and thus
For pathway metabolites, there is generally a very high turnover of the metabolite pool. As a result, the concentrations of the different metabolite pools rapidly adjust to new levels even after large perturbations in the environment experienced by the cells. It is therefore reasonable to assume that the pathway metabolites are at a pseudosteady state. 68 By separating v into measured and unknown components, v m and v u , respectively, and partitioning matrix S into S m and S u , where S m and S u contain the stoichiometric coefficients of measured and unknown reactions, respectively, we obtained:
Combining equations [2] and [3] results in the following relationship:
In both model states, the number of linearly independent equations exceeded the number of unknown fluxes. Thus, redundant equations were present, and the mass-balance method of Wang and Stephanopoulos 69 was applied to test the measurements in v m for the presence of any gross errors. In this method, redundant constraints are used in conjunction with an error variance-covariance matrix () to calculate a test function (h) that represents the weighted square of the residuals of the constraints. The test function h, which for normally and randomly distributed errors follows the 2 distribution, is used to test the hypothesis that the amount of errors present in the measurements is not significant with a confidence level of 1 Ϫ , where is a parameter expressing the tail area probability of a 2 distribution. This hypothesis is rejected if the test function value is greater than 1Ϫ 2 (m), where m represents the number of redundant constraints. The system of linear equations describing model state I consists of 33 linearly independent equations and 58 fluxes, 29 of which are known (27 measured and 2 assumed). Thus, the degree of redundancy for model state I, or m I , is 4. Model state II is described by a system of 33 linearly independent equations and 58 fluxes, 29 of which are known (27 measured and 2 assumed), and consequently m II is 4. was estimated by a diagonal matrix whose components were the animal-to-animal variances associated with each measurement, where it was assumed that each measurement error is independent of one another and uncorrelated.
For each liver perfused, we determined the compatibility of the measurements with either the gluconeogenic or glycolytic model state by calculating a corresponding test function value for each model state Ϫ measurement pairing, i.e., two h values were calculated for each set of measurements, one with pyruvate kinase and pyruvate dehydrogenase fluxes set to 0, and another with pyruvate carboxylase and pyruvate dehydrogenase flux set to 0. The combination of model state and measurement set resulting in the lower test function value was considered to have greater consistency with the assumed biochemistry, and was used to calculate reaction rates. Because S u is not a square matrix, i.e., the number of rows is greater than the number of columns, equation [4] cannot be solved by simple inversion. One approach was to use the Moore-Penrose pseudo-inverse method, in which each side of equation [4] is multiplied by the transpose of S u :
The matrix multiplier of v u is now invertible, and equation [5] is easily solved:
It should be noted that the calculated fluxes are algebraic solutions to overdetermined linear systems, and thus are analogous to straightline parameters (slope and intercept) determined by linear regression. The vector v u represents the best global fit to the linear system given by equation [6] , but individual vector elements may not exactly satisfy local constraints, i.e., a flux balance around a particular metabolite may not close completely, similar to the way individual points may not lie on the linearly regressed line found by minimizing the sum of the least-square distances between all of the points and the line. Solutions to equation [5] were obtained with a program written in MATLAB RN (Mathworks, Inc., Natick, MA) and routinely took less than 1 minute for each measurement set on an IBM ThinkPad laptop computer with a Celeron 466-mHz processor. The fluxes obtained by equation [6] for each liver were reported as averages for each group (FHF and control) in Table 2 .
Evaluation of Efficiency of Fitting Procedure. To assess how close calculated fluxes match with measured data as well as their internal consistency, we compared fluxes coming into and out of key points in selected representative regions of the metabolic network. For example, the measured flux no. 1 (measured glucose output) should exactly match the calculated fluxes nos. 2, 3, and 4. There was no statistically significant difference between these in either control or FHF rat livers ( Table 5 ). The trend toward a decreasing flux in the FHF group nevertheless suggests that a better fit may be achieved by adding certain reactions in this part of the network that were ignored (e.g., pentose phosphate pathway, glycogen synthesis). We then compared the measured oxygen uptake (flux no. 57) with predicted uptake based on the calculated fluxes of reactions using oxygen and found excellent agreement between the two in both control and FHF rat livers. The calculated production of acetyl CoA and its calculated consumption rates also matched, which is a good indication of the internal consistency of the model. Comparing measured urea synthesis rates (flux no. 18) with calculated rates based on neighboring urea cycle fluxes revealed no significant difference in the control group, and a 20% to 25% difference (P Ͻ .05) in the FHF group, although the changes observed in response to FHF were very similar.
Sensitivity Analysis of Model Calculations to Steady-State Assumption. In the preceding estimation procedure, we assumed that the steadystate assumptions are exactly satisfied. If there is noise in the pseudosteady state equations (meaning that small accumulations of the corresponding metabolites are possible), then an estimate of the intracellular fluxes can be found by the method of Tsai and Lee. 70 In this method, the mass balances of equation [4] are rewritten in a more general form: The solution to equation [7] is given by:
where v represents a least-square estimate of both the unknown and measured fluxes. The residuals of both the measured fluxes and the pseudo-steady-state assumptions can be incorporated into a variance-covariance matrix F:
If the residuals are uncorrelated and independent of each other, F is a diagonal matrix of dimension D, where D is given by the sum of the number of measured fluxes and steady-state metabolite balances. The flux estimate given by equation [9] differs from that given by equation [6] in that the more general partitioning between measurement and unknown vectors allows adjustments to be made to the measured fluxes that incorporate knowledge regarding measurement and pseudo-steady-state assumption noises. Thus, in equation [9] , all of the fluxes, including the measured ones, are treated as vari- ables, which in turn depend on the measured fluxes, whereas in equation [6] , there is a strict separation between measured and unknown fluxes, so that only the unknown fluxes depend on the measured fluxes. The two methods described above yield identical results if the measurements (and the steady-state assumptions) are noisefree and no adjustments can be made to improve the sum of residuals. In this study, the method of Tsai and Lee was used to gauge the effect of small (10% or less) experimental noise (as a result of measurement errors, animal-to-animal variations, and steady-state assumptions) on the calculated fluxes by examining the differences between the corresponding flux values obtained by equations [6] and [9] . We found that the most sensitive parameter, oxygen uptake rate (flux no. 58), changed by about 20 mol/g dry liver/h and 15 mol/g dry liver/h for the control and FHF rat livers, respectively. These variations represent less than 10% of the flux values.
